About

Gastrointestinal stromal tumors (GISTs) are the most common connective tissue cancers of the digestive tract, and their growth is typically driven by mutations in a gene called KIT. Bezulcastinib is a pill designed to selectively block the specific, mutated form of the KIT protein that fuels these tumors. By precisely targeting this faulty driver, the drug could potentially stop tumor growth in patients whose cancers have become resistant to other treatments.